Co-Authors
This is a "connection" page, showing publications co-authored by Olatoyosi Odenike and Caner Saygin.
Connection Strength
1.542
-
Targeting Menin in T-lineage Acute Lymphoblastic Leukemia. Mol Cancer Ther. 2026 Aug 04; 25(8):1294-1304.
Score: 0.247
-
Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults. Blood Cancer J. 2025 08 14; 15(1):138.
Score: 0.231
-
Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis. Blood Cancer Discov. 2024 05 01; 5(3):164-179.
Score: 0.211
-
Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults. Blood Adv. 2024 01 09; 8(1):164-171.
Score: 0.207
-
Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia. Clin Cancer Res. 2023 08 15; 29(16):3151-3161.
Score: 0.201
-
Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies. Blood Adv. 2021 04 27; 5(8):2264-2271.
Score: 0.172
-
Association of sarcopenia with treatment tolerance in older adults with acute myeloid leukemia using artificial intelligence computed tomography-segmentation and a geriatric assessment. Leukemia. 2026 Aug 31.
Score: 0.062
-
Outcomes of patients with relapsed/refractory acute leukaemia treated with revumenib with a focus on post-revumenib therapies. Br J Haematol. 2026 Jan; 208(1):343-347.
Score: 0.059
-
Outcomes for Patients With Myeloid Neoplasms Treated With Chemotherapy Plus Venetoclax After Prior Venetoclax Therapy. EJHaem. 2025 Jun; 6(3):e70078.
Score: 0.057
-
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy. Leuk Lymphoma. 2024 06; 65(6):864-867.
Score: 0.052
-
OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia. Blood Cancer J. 2021 03 03; 11(3):48.
Score: 0.042